Campylobacter jejuni cDNA and Antigen

Campylobacter jejuni is a gram-negative, microaerophilic bacterium that is a leading cause of foodborne illness worldwide. Its virulence and pathogenicity are associated with various surface proteins and antigens that enable it to colonize the intestinal tract and evade the host immune response.

Some of the major antigen and surface proteins of Campylobacter jejuni include:

PEB4A: This protein is a periplasmic protein that is involved in the transport of iron ions into the bacterial cell. It is also involved in the formation of biofilms, which are important for the survival of the bacterium in harsh environmental conditions.

CBF1: This protein is a major antigenic protein of Campylobacter jejuni that is involved in the colonization of the intestinal tract. It is also involved in the adherence of the bacterium to the intestinal epithelium and the formation of biofilms.

PEB1: This protein is a periplasmic protein that is involved in the transport of iron ions into the bacterial cell. It is also involved in the formation of biofilms and is a major antigenic protein of Campylobacter jejuni.

D15: This protein is a major antigenic protein of Campylobacter jejuni that is involved in the colonization of the intestinal tract. It is also involved in the adherence of the bacterium to the intestinal epithelium.

CjaA: This protein is a major antigenic protein of Campylobacter jejuni that is involved in the colonization of the intestinal tract. It is also involved in the adherence of the bacterium to the intestinal epithelium and the formation of biofilms.

These proteins are potential targets for the development of vaccines and diagnostic assays for Campylobacter jejuni infections. Vaccines that target these proteins could provide protection against infection, while diagnostic assays that detect the presence of these proteins could aid in the diagnosis and treatment of Campylobacter jejuni infections.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.

One application of C. jejuni cDNA is in the identification of virulence factors. By sequencing and analyzing cDNA libraries, researchers can identify genes that are important for the pathogenesis of the bacterium, providing insights into the mechanisms of infection.

Recombinant antigens derived from C. jejuni have also been used in the development of diagnostic tests for Campylobacter infection. These tests are based on the detection of antibodies against specific antigens in the patient’s serum. Recombinant antigens have been shown to have improved sensitivity and specificity compared to traditional diagnostic tests, making them useful tools for the rapid and accurate diagnosis of Campylobacter infection.

Another application of recombinant antigens is in the development of a vaccine for Campylobacter. Several recombinant antigens have been shown to elicit a protective immune response in animal models and are being evaluated in preclinical and clinical trials.

In conclusion, the application of C. jejuni cDNA and recombinant antigens has the potential to contribute to the development of more effective diagnostic tests and a vaccine for Campylobacter infection, which can help to reduce the burden of this disease on public health.